{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-010177","form_type":"8-K","ticker":"PMVP","cik":"0001699382","company_name":"PMV Pharmaceuticals, Inc.","filed_at":"2024-01-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.161679+00:00","generated_at":"2026-06-06T21:58:44.643103+00:00","sec_items":["2.05","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"PMV Pharma cuts workforce 30%, extends cash runway to end of 2026","bullets":["Workforce reduction of ~30% to prioritize PC14586 development and streamline operations.","Unaudited cash, cash equivalents, and marketable securities of ~$229M as of Dec 31, 2023.","Expected non-recurring charges of ~$1.4M for employee severance and benefits, mainly in Q1 2024.","Cash runway now expected to extend to end of 2026 due to cost savings.","Registrational Phase 2 trial for PC14586 remains on track to initiate in Q1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-010177","json":"https://secwatch.observer/filing/0001193125-24-010177.json","markdown":"https://secwatch.observer/filing/0001193125-24-010177.md","text":"https://secwatch.observer/filing/0001193125-24-010177.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699382/000119312524010177/0001193125-24-010177-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699382/000119312524010177/d695291d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T21:58:44.643103+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"722c13f962c78cdaab73212c05ed02f36bccdef4","claim":"PMV Pharmaceuticals, Inc. announced a restructuring with charges of approximately $1.4 million (approximately 30% of the Company’s employees).","evidence_excerpt":"development for its lead product candidate, PC14586. As a result of the reduction in force, the Company expects to incur aggregate non-recurring charges of approximately $1.4 million, consisting primarily of employee severance and benefit costs associated with the restructuring. The Company expects that most of these charges will be cash expenditures and that","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1699382/000119312524010177/0001193125-24-010177-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $1.4 million"},{"label":"Headcount","value":"approximately 30% of the Company’s employees"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}